Basic Information
RNALocate ID: | RLID:11001903 |
RNA Symbol: | hsa-miR-146a-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-146a-5p |
RNA ID: | miRBase:MIMAT0000449 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22211110 |
Tissue/Cell Line: | Breast milk |
Method: | Next-generation RNA sequencing |
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001827 | Endoplasmic reticulum membrane | Cortical tissue | 32451872 |
RLID:01001828 | Mitochondrion | Osteosarcoma cell line (143B) | 27396686 |
RLID:01001829 | Mitochondrion | Osteosarcoma cell line (143B) | 27563705 |
RLID:01001830 | Mitochondrion | Human umbilical vein endothelial cells | 30348904 |
RLID:11001900 | Exosome | Plasma | 19289371 |
RLID:11001901 | Exosome | Primary dendritic cells | 21505438 |
RLID:11001902 | Exosome | Renal cancer cells | 21670082 |
RLID:11001904 | Exosome | Brain tissue | 23382797 |
RLID:11001905 | Exosome | Plasma | 23663360 |
RLID:11001906 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001907 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11001908 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001909 | Microvesicle | Plasma | 23077538 |
RLID:11001910 | Microvesicle | Seminal plasma | 23539611 |
RLID:11001911 | Microvesicle | Follicular fluid | 23666971 |
RLID:11001912 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000097 | Exosome | Blood|B lymphoblastoid cells|Endothelial cells|Epithelial cells|Lymphoma tissue|Mast cells|Tongue tissue | |
RLID-D:11000377 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-146a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-15282 |
MNDR | hsa-miR-146a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-15283 |
MNDR | hsa-miR-146a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-15284 |
MNDR | hsa-miR-146a-5p | Oral squamous cell carcinoma | MNDR-E-MI-15285 |
MNDR | hsa-miR-146a-5p | Medulloblastoma | MNDR-E-MI-15286 |
MNDR | hsa-miR-146a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-15287 |
MNDR | hsa-miR-146a-5p | Lymphoma | MNDR-E-MI-15288 |
MNDR | hsa-miR-146a-5p | Lymphoma non-hodgkin | MNDR-E-MI-15289 |
MNDR | hsa-miR-146a-5p | Cutaneous t cell lymphoma | MNDR-E-MI-15290 |
MNDR | hsa-miR-146a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-15291 |
MNDR | hsa-miR-146a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-15292 |
MNDR | hsa-miR-146a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-15293 |
MNDR | hsa-miR-146a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-15294 |
MNDR | hsa-miR-146a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-15295 |
MNDR | hsa-miR-146a-5p | Triple negative breast cancer | MNDR-E-MI-15296 |
MNDR | hsa-miR-146a-5p | Colitis | MNDR-E-MI-15297 |
MNDR | hsa-miR-146a-5p | Acute promyelocytic leukemia | MNDR-E-MI-15298 |
MNDR | hsa-miR-146a-5p | Breast cancer luminal | MNDR-E-MI-15299 |
MNDR | hsa-miR-146a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-15300 |
MNDR | hsa-miR-146a-5p | Anaplastic thyroid carcinoma | MNDR-E-MI-15301 |
MNDR | hsa-miR-146a-5p | Dermatomyositis | MNDR-E-MI-15302 |
MNDR | hsa-miR-146a-5p | Castration-resistant prostate cancer | MNDR-E-MI-15303 |
MNDR | hsa-miR-146a-5p | Hirschsprung disease | MNDR-E-MI-15304 |
MNDR | hsa-miR-146a-5p | Gastric cancer | MNDR-E-MI-15305 |
MNDR | hsa-miR-146a-5p | Gastric lymphoma | MNDR-E-MI-15306 |
MNDR | hsa-miR-146a-5p | Alzheimer disease | MNDR-E-MI-15307 |
MNDR | hsa-miR-146a-5p | Intracranial aneurysm | MNDR-E-MI-15308 |
MNDR | hsa-miR-146a-5p | Urinary bladder cancer | MNDR-E-MI-15309 |
MNDR | hsa-miR-146a-5p | Esophageal carcinoma | MNDR-E-MI-15310 |
MNDR | hsa-miR-146a-5p | Osteoporosis | MNDR-E-MI-15311 |
MNDR | hsa-miR-146a-5p | Dysautonomia familial | MNDR-E-MI-15312 |
MNDR | hsa-miR-146a-5p | Familial hyperlipidemia | MNDR-E-MI-15313 |
MNDR | hsa-miR-146a-5p | Seizures | MNDR-E-MI-15314 |
MNDR | hsa-miR-146a-5p | Head and neck cancer | MNDR-E-MI-15315 |
MNDR | hsa-miR-146a-5p | Creutzfeldt-jakob syndrome | MNDR-E-MI-15316 |
MNDR | hsa-miR-146a-5p | Dengue disease | MNDR-E-MI-15317 |
MNDR | hsa-miR-146a-5p | Vogt-koyanagi-harada disease | MNDR-E-MI-15318 |
MNDR | hsa-miR-146a-5p | Huntington disease | MNDR-E-MI-15319 |
MNDR | hsa-miR-146a-5p | Chorea | MNDR-E-MI-15320 |
MNDR | hsa-miR-146a-5p | Cardiovascular disease | MNDR-E-MI-15321 |
MNDR | hsa-miR-146a-5p | Carotid stenosis | MNDR-E-MI-15322 |
MNDR | hsa-miR-146a-5p | Moyamoya disease | MNDR-E-MI-15323 |
MNDR | hsa-miR-146a-5p | Lung cancer | MNDR-E-MI-15324 |
MNDR | hsa-miR-146a-5p | Giant cell arteritis | MNDR-E-MI-15325 |
MNDR | hsa-miR-146a-5p | Tuberous sclerosis | MNDR-E-MI-15326 |
MNDR | hsa-miR-146a-5p | Parkinson disease | MNDR-E-MI-15327 |
MNDR | hsa-miR-146a-5p | Basal-like breast cancer | MNDR-E-MI-15328 |
MNDR | hsa-miR-146a-5p | Vascular diseases | MNDR-E-MI-15329 |
MNDR | hsa-miR-146a-5p | Thyroid cancer | MNDR-E-MI-15330 |
MNDR | hsa-miR-146a-5p | Pituitary neoplasms | MNDR-E-MI-15331 |
MNDR | hsa-miR-146a-5p | Pancreatic cancer | MNDR-E-MI-15332 |
MNDR | hsa-miR-146a-5p | Epilepsy | MNDR-E-MI-15333 |
MNDR | hsa-miR-146a-5p | Hepatitis C | MNDR-E-MI-15334 |
MNDR | hsa-miR-146a-5p | Melanoma | MNDR-E-MI-15335 |
MNDR | hsa-miR-146a-5p | Atherosclerosis | MNDR-E-MI-15336 |
MNDR | hsa-miR-146a-5p | Rectum adenocarcinoma | MNDR-E-MI-15337 |
MNDR | hsa-miR-146a-5p | Nephroblastoma | MNDR-E-MI-15338 |
MNDR | hsa-miR-146a-5p | Colon cancer | MNDR-E-MI-15339 |
MNDR | hsa-miR-146a-5p | Ischemic attack transient | MNDR-E-MI-15340 |
MNDR | hsa-miR-146a-5p | Colon adenocarcinoma | MNDR-E-MI-15341 |
MNDR | hsa-miR-146a-5p | Multiple sclerosis | MNDR-E-MI-15342 |
MNDR | hsa-miR-146a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-15343 |
MNDR | hsa-miR-146a-5p | Familial ovarian cancer | MNDR-E-MI-15344 |
MNDR | hsa-miR-146a-5p | Dermatitis | MNDR-E-MI-15345 |
MNDR | hsa-miR-146a-5p | Pulmonary tuberculosis | MNDR-E-MI-15346 |
MNDR | hsa-miR-146a-5p | Glioblastoma | MNDR-E-MI-15347 |
MNDR | hsa-miR-146a-5p | Astrocytoma | MNDR-E-MI-15348 |
MNDR | hsa-miR-146a-5p | Glioma | MNDR-E-MI-15349 |
MNDR | hsa-miR-146a-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-15350 |
MNDR | hsa-miR-146a-5p | Gastrointestinal system cancer | MNDR-E-MI-15351 |
MNDR | hsa-miR-146a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-15352 |
MNDR | hsa-miR-146a-5p | Epilepsy temporal lobe | MNDR-E-MI-15353 |
MNDR | hsa-miR-146a-5p | Osteosarcoma | MNDR-E-MI-15354 |
MNDR | hsa-miR-146a-5p | Inclusion body myositis | MNDR-E-MI-15355 |
MNDR | hsa-miR-146a-5p | Infarction middle cerebral artery | MNDR-E-MI-15356 |
MNDR | hsa-miR-146a-5p | Meningioma | MNDR-E-MI-15357 |
MNDR | hsa-miR-146a-5p | Liver cancer | MNDR-E-MI-15358 |
MNDR | hsa-miR-146a-5p | Uterine cancer | MNDR-E-MI-15359 |
MNDR | hsa-miR-146a-5p | Gastric adenocarcinoma | MNDR-E-MI-15360 |
MNDR | hsa-miR-146a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-15361 |
MNDR | hsa-miR-146a-5p | Pituitary adenoma | MNDR-E-MI-15362 |
MNDR | hsa-miR-146a-5p | Lung squamous cell carcinoma | MNDR-E-MI-15363 |
MNDR | hsa-miR-146a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-15364 |
MNDR | hsa-miR-146a-5p | Lung adenocarcinoma | MNDR-E-MI-15365 |
MNDR | hsa-miR-146a-5p | Adrenocortical carcinoma | MNDR-E-MI-15366 |
MNDR | hsa-miR-146a-5p | Thyroid carcinoma | MNDR-E-MI-15367 |
MNDR | hsa-miR-146a-5p | Papillary thyroid carcinoma | MNDR-E-MI-15368 |
MNDR | hsa-miR-146a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-15369 |
MNDR | hsa-miR-146a-5p | Hypersensitivity reaction type ii disease | MNDR-E-MI-15370 |
MNDR | hsa-miR-146a-5p | Brain stem cancer | MNDR-E-MI-15371 |
MNDR | hsa-miR-146a-5p | Coronary restenosis | MNDR-E-MI-15372 |
MNDR | hsa-miR-146a-5p | Gerstmann-straussler-scheinker disease | MNDR-E-MI-15373 |
MNDR | hsa-miR-146a-5p | Cervical cancer | MNDR-E-MI-15374 |
MNDR | hsa-miR-146a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-15375 |
MNDR | hsa-miR-146a-5p | Carcinoma renal cell | MNDR-E-MI-15376 |
MNDR | hsa-miR-146a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-15377 |
MNDR | hsa-miR-146a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-15378 |
MNDR | hsa-miR-146a-5p | Biliary tract cancer | MNDR-E-MI-15379 |
MNDR | hsa-miR-146a-5p | Medulloepithelioma | MNDR-E-MI-15380 |
MNDR | hsa-miR-146a-5p | Cholangiocarcinoma | MNDR-E-MI-15381 |
MNDR | hsa-miR-146a-5p | Esophageal cancer | MNDR-E-MI-15382 |
MNDR | hsa-miR-146a-5p | Scrapie | MNDR-E-MI-15383 |
MNDR | hsa-miR-146a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-15384 |
MNDR | hsa-miR-146a-5p | Acute t cell leukemia | MNDR-E-MI-15385 |
MNDR | hsa-miR-146a-5p | Heart failure | MNDR-E-MI-15386 |
MNDR | hsa-miR-146a-5p | Fibromyalgia | MNDR-E-MI-15387 |
MNDR | hsa-miR-146a-5p | Pulmonary hypertension | MNDR-E-MI-15388 |
MNDR | hsa-miR-146a-5p | Cerebrovascular disease | MNDR-E-MI-15389 |
MNDR | hsa-miR-146a-5p | Juvenile rheumatoid arthritis | MNDR-E-MI-15390 |
MNDR | hsa-miR-146a-5p | Hepatocellular carcinoma | MNDR-E-MI-15391 |
MNDR | hsa-miR-146a-5p | Familiar ovarian carcinoma | MNDR-E-MI-15392 |
MNDR | hsa-miR-146a-5p | B-cell lymphoma | MNDR-E-MI-15393 |
MNDR | hsa-miR-146a-5p | Ankylosing spondylitis | MNDR-E-MI-15394 |
MNDR | hsa-miR-146a-5p | Rheumatoid arthritis | MNDR-E-MI-15395 |
MNDR | hsa-miR-146a-5p | T-cell leukemia | MNDR-E-MI-15396 |
MNDR | hsa-miR-146a-5p | Retinoblastoma | MNDR-E-MI-15397 |
MNDR | hsa-miR-146a-5p | Neuroblastoma | MNDR-E-MI-15398 |
MNDR | hsa-miR-146a-5p | Chronic fatigue syndrome | MNDR-E-MI-15399 |
MNDR | hsa-miR-146a-5p | Hodgkin disease | MNDR-E-MI-15400 |
MNDR | hsa-miR-146a-5p | Ulcerative colitis | MNDR-E-MI-15401 |
MNDR | hsa-miR-146a-5p | Burkitt lymphoma | MNDR-E-MI-15402 |
MNDR | hsa-miR-146a-5p | Kaposi sarcoma | MNDR-E-MI-15403 |
MNDR | hsa-miR-146a-5p | Dementia vascular | MNDR-E-MI-15404 |
MNDR | hsa-miR-146a-5p | Crohn disease | MNDR-E-MI-15405 |
MNDR | hsa-miR-146a-5p | Tonsil cancer | MNDR-E-MI-15406 |
MNDR | hsa-miR-146a-5p | Neuromyelitis optica | MNDR-E-MI-15407 |
MNDR | hsa-miR-146a-5p | Psoriasis | MNDR-E-MI-15408 |
MNDR | hsa-miR-146a-5p | Skin cutaneous melanoma | MNDR-E-MI-15409 |
MNDR | hsa-miR-146a-5p | Skin melanoma | MNDR-E-MI-15410 |
MNDR | hsa-miR-146a-5p | Subacute sclerosing panencephalitis | MNDR-E-MI-15411 |
MNDR | hsa-miR-146a-5p | Acute myelocytic leukemia | MNDR-E-MI-15412 |
MNDR | hsa-miR-146a-5p | Colorectal cancer | MNDR-E-MI-15413 |
MNDR | hsa-miR-146a-5p | Type 2 diabetes mellitus | MNDR-E-MI-15414 |
MNDR | hsa-miR-146a-5p | Diabetic neuropathy | MNDR-E-MI-15415 |
MNDR | hsa-miR-146a-5p | Acute lymphocytic leukemia | MNDR-E-MI-15416 |
MNDR | hsa-miR-146a-5p | Seizures febrile | MNDR-E-MI-15417 |
MNDR | hsa-miR-146a-5p | Ependymoma | MNDR-E-MI-15418 |
MNDR | hsa-miR-146a-5p | Graft vs host disease | MNDR-E-MI-15419 |
MNDR | hsa-miR-146a-5p | Cardiomegaly | MNDR-E-MI-15420 |
MNDR | hsa-miR-146a-5p | Nasopharyngeal cancer | MNDR-E-MI-15421 |
MNDR | hsa-miR-146a-5p | Prostatic neoplasms | MNDR-E-MI-15422 |
MNDR | hsa-miR-146a-5p | Wounds and injuries | MNDR-E-MI-15423 |
MNDR | hsa-miR-146a-5p | Muscle weakness | MNDR-E-MI-15424 |
MNDR | hsa-miR-146a-5p | Epstein-barr virus infections | MNDR-E-MI-15425 |
MNDR | hsa-miR-146a-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-15426 |
MNDR | hsa-miR-146a-5p | Gait ataxia | MNDR-E-MI-15427 |
MNDR | hsa-miR-146a-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-15428 |
MNDR | hsa-miR-146a-5p | Stroke | MNDR-E-MI-15429 |
MNDR | hsa-miR-146a-5p | Encephalitis herpes simplex | MNDR-E-MI-15430 |
MNDR | hsa-miR-146a-5p | Nk/t cell lymphoma | MNDR-E-MI-15431 |
MNDR | hsa-miR-146a-5p | Stroke lacunar | MNDR-E-MI-15432 |
MNDR | hsa-miR-146a-5p | Breast cancer her3+ negative | MNDR-E-MI-15433 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABL2 | Homo sapiens | RR00027153 |
TOP